On Fri, 27 Oct 1995 14:21:59 GMT,
Keneth Grandchamp <grandcha at cmu.unige.ch > wrote:
>This article was written by Claude Rifat, using Kenneth Grandchamp's account.
Claude:
Would I be correct in assuming that you work in medicinal chemistry
research at the University of Geneva?
Several of the SSRIs that you mention are now available in the U.S.
Some of your theories concerning the psychological effects of
psychotropic medications do not appear to correspond with standard
scientific opinion (at least as I understand it). Do you have
citations to back them up?
You and your associates in the Swiss and French pharmaceutical
industries may be interested in the following references:
Mirovsky Y, Yu YL, Wagner GC, Sekowski A, Goldberg M, Fisher H.
Novel Synergistic Treatment of Ethanol Withdrawal Seizures in Rats
with Dopamine and Serotonin Agonists. Alcoholism, Clinical and
Experimental Research 19:1 160-163 (1995).
Chrousos GP, Gold PW. The Concepts of Stress and Stress System
Disorders: Overview of Physical and Behavioral Homeostasis. JAMA
267:9 1244-1252 (1992).
Mirovsky et al used amphetamine + fenfluramine. A similar
combination - phentermine + fenfluramine - is used in the treatment
of obesity. There is anecdotal evidence that these types of
combinations have a spectrum of efficacy somewhat similar to
but even broader than steroids, but without the long term adverse
effects.
I may be jumping the gun a little here, but the evidence I've seen
shows these combinations of generic medications as having the
potential for decimating the market for many existing patented
psychotropic medications (Bye, bye, Prozac!). Indirect agonists and
precursors of dopamine and serotonin seem to work best in these
combinations, as opposed to direct agonists and uptake blockers.
AJR
